

Below is a list of presentations that will be given by OSUCCC – James experts at #ASH25.

Ohio State at 2025 ASH® Annual Meeting

Friday, December 5

SATELLITE SYMPOSIA

11 a.m. | Session will be livestreamed during the scheduled time.

Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

SYMPOSIA/SCIENTIFIC WORKSHOPS:

3:44 p.m.

Speaker: Aging and Hematology: Engineering the Immune System to Reverse Hematologic Aging

Ashley Rosko, MD

12:45 – 5 p.m.

Speaker: ASH-a-Palooza Program: Blood Buddies | PhD/Lab

Raj Muthusamy, DVM, PhD

1:30 – 4 p.m.

Mentor: ASH-a-Palooza Program: Blood Buddies | Medical Education

Kathryn Lurain, MD

2:40 p.m.

Speaker: ASH-a-Palooza Program: Blood Drops: International Medical Graduates

Sumithira Vasu, MBBS

Saturday, December 6

EDUCATION/SPECIAL INTEREST SESSIONS:

9:30 a.m.

Chair: Leveraging Genetic Diversity In Preclinical Discovery To Guide Precision Medicine (Special Interest Session)

Ann-Kathrin Eisfeld, MD

9:30 a.m.

Moderator: Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative AI and Omics Approaches in Hematologic Malignancies (Session 803)

Andrew Srisuwananukorn, MD

9:30 a.m.

Moderator: Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders:
Clinical decision making and supportive care (Session 906)

Seema Bhat, MD

12 p.m.

Moderator: Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools (Session 624)

Timothy Voorhees, MD, MSCR

ORAL PRESENTATIONS

10 a.m.

CLL | Abstract #2620

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Authors: **Jennifer Woyach** 1, Danielle Brander², Boyu Hu³, **Kerry Rogers**⁴, Zulfa Omer⁵, Emily Curran⁶, Deborah Stephens⁷, Andrea Sitlinger⁸, Yi Chen⁹, Stephen Anthony⁹, Yu Chen⁹, Kewei Shang⁹, John Byrd¹⁰

2 p.m.

AML | Abstract #7120

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Authors: Audrey Lasry 1, Bettina Nadorp^{1, 2}, Sanam Loghavi³, Ravi Patel⁴, Hager Mansour^{5, 6, 7}, Ben Kelly⁸, Christopher Walker^{4, 9}, Jill Buss^{4, 9}, Isaiah Boateng⁴, Wafa Al-Santli¹, Zoe Ciantra¹, Rebecca Austin¹, Adrienne Heyrosa⁴, Helee Desai⁴, Andrea Laganson⁴, Hasan Abaza⁴, Linda Procell¹, Tejas Patel¹, Benjamin Kaffenberger⁴, Saranga Wijeratne⁸, Maria Guillaumot¹, **Maria Velegraki**¹⁰, Luis Chiriboga¹, Zihai Li¹⁰, Lynne Abruzzo³, Daniel Pollyea¹¹, Christine McMahon¹¹, Arwa Shana'Ah⁴, John Byrd⁴, Alan Shih¹², Ross Levine¹³, Eirini Papapetrou^{5, 6, 7}, Aristotelis Tsigos^{1, 2}, Elaine Mardis^{4, 8, 14}, **Alice Mims**¹⁰, Iannis Aifantis¹, **Ann-Kathrin Eisfeld**⁴,

2 p.m.

Lymphoma | Abstract #2341

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Authors: Saurabh Dahiya 1, Matthew Ulrickson², Jean Yared³, Patrick Reagan⁴, **Timothy Voorhees**⁵, Ran Reshef⁶, Cameron Turtle⁷, Lizamarie Bachier-Rodriguez⁸, Marie José Kersten⁹, Prof. Dr. Max S Topp¹⁰, Gary Simmons¹¹, Robin Sanderson¹², Loretta Nastoupil¹³, Scott

*Jung*¹⁴, *Enrique Granados*¹⁴, *Jinghui Dong*¹⁴, *Joshua Winters*¹⁴, *Rhine Shen*¹⁴, *Justyna Kanska*¹⁴, *Myrna Nahas*¹⁴, *Sairah Ahmed*¹⁵

2:15 p.m.

CH:Basic/Translational | Abstract #10344

Garp/LRRC32 defines the erythroid-megakaryocyte fate decision and enables β -globin program activation

Authors: ***Maria Velegraki***¹, ***Bradley Blaser***², *Payton Weltge*¹, *Jordan Krull*^{1, 3}, *Maryam Soltani-asl*¹, *Emanuele Cocucci*⁴, *Haitao Wen*⁵, *Qin Ma*^{1, 3}, *Anjun Ma*^{1, 3}, *Zihai Li*

2:45 p.m.

AML | Abstract #11323

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Authors: ***Uma Borate***¹, ***Shivani Handa***¹, *Kaitlyn Dvorak-Kornaus*¹, *Ronan Swords*², *Curtis Lachowicz*², ***Qihong Zhao***¹, *Yazan Madanat*³

2:45 p.m.

AML | Abstract #13937

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Authors: *Christine McMahon*¹, *Deedra Nicolet*², *Alice Mims*², *Charles Foucar*³, *Yazan Madanat*⁴, *Brittany Ragon*⁵, *Kieran Sahasrabudhe*⁶, *Onyee Chan*⁷, *Joshua Zeidner*⁸, *Michael Hochman*⁹, *Daniel Pollyea*¹⁰, *Krzysztof Mrózek*², *Michael Walker*², *Fnu Amritpal Singh*¹, *Tara Lin*¹¹, *Bianca Barredo*⁶, *Lauren Banaszak*⁶, *Jesus Gonzalez-Lugo*⁶, *Alex Ambinder*¹², ***Ann-Kathrin Eisfeld***²

2:45 p.m.

CLL | Abstract #1877

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Authors: *Chan Cheah*¹, *Manish Patel*², *Toby Eyre*³, *Wojciech Jurczak*⁴, *David Lewis*⁵, *Thomas Gastinne*⁶, *Shuo Ma*⁷, *Jonathon Cohen*⁸, *Krish Patel*⁹, *Jennifer Brown*¹⁰, *Lydia Scarfo*¹¹, *Talha Munir*¹², *Ewa Lech-Maranda*¹³, *Marc Hoffmann*¹⁴, *Chaitra Ujjani*¹⁵, *Bita Fakhri*¹⁶, *Michael Wang*¹⁷, *Koji Izutsu*¹⁸, *Hirokazu Nagai*¹⁹, *Constantine Tam*²⁰, *Joanna Rhodes*²¹, *Julie Vose*²², *Matthew McKinney*²³, *James Gerson*²⁴, *Minal Barve*²⁵, *Bryone Kuss*²⁶, *Youngil Koh*²⁷, *Aisling Barrett*³, *Steven Treon*²⁸, *Jorge Castillo*²⁸, *John Seymour*²⁹, *Amy Ruppert Stark*³⁰, *Samuel McNeely*³⁰, *Richard Walgren*³⁰, *Donald Tsai*³⁰, *Katherine Bao*³⁰, *Binoj Chandrasekharan Nair*³⁰, ***Jennifer Woyach***³¹, *Lia Palomba*

3:15 p.m.

AML | Abstract #10258

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Authors: Jesus Gonzalez-Lugo 1 , Alex Ambinder2, Deedra Nicolet3, Krzysztof Mrózek3, Maire Okoniewski1, Yazan Madanat4, Michael Walker3, Charles Foucar5, Christine McMahon6, Michael Hochman7, Brittany Ragon8, Joshua Zeidner9, Kieran Sahasrabudhe10, Anna Bode5, Bianca Barredo10, Lauren Banaszak10, Rami Komrokji11, Alice Mims3, Onyee Chan11, Tara Lin1, **Ann-Kathrin Eisfeld3**

5 p.m.

Lymphoma | Abstract #2078

Integrated multi-omic profiling reveals two biologically distinct subgroups of splenic marginal zone lymphoma with prognostic relevance

Authors: Helen Parker1, Ben Stevens 1 , Amatta Mirandari1, Carolina Jaramillo-Oquendo1, Marti Duran-ferrer2, Lara Buermann1, Harindra Amarasinghe3, Jaya Thomas1, Louise Carr1, Shama Syeda1, Methusha Sakthipakan1, Marina Parry1, Matthew Rose-Zerilli1, Zadie Davis4, Neil McIver-Brown4, Aliko Xochelli5, Sarah Ennis6, Lydia Scarfo7, Paolo Ghia7, 8, Christina Kalpadakis9, Gerassimos Pangalis10, Davide Rossi11, Matthew Ahearne12, Marc PD Dr. Seifert13, Christoph Plass14, Dieter Weichenhan14, Eva Kimby15, Lesley Ann Sutton15, Richard Rosenquist15, Guy Pratt16, Francesco Forconi1, Kostas Stamatopoulos5, Marta Salido17, Raja PrinceEladnani17, Catherine Thieblemont18, Laura Hilton19, Ryan Morin19, Renata Walewska4, Jose MartinSubero2, 20, David Oscier4, **Christopher Oakes21**, Jane Gibson1, Dean Bryant1, Jonathan Strefford1

5:30 p.m.

CLL | Abstract #7068

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Authors: Michael Wang 1 , Jonathon Cohen2, Nirav Shah3, Wojciech Jurczak4, Pier Luigi Zinzani5, Chan Cheah6, Chaitra Ujjani7, Youngil Koh8, Won Seog Kim9, Sunita Dwivedy Nasta10, Ian Flinn11, Benoit Tessoulin12, Shuo Ma13, Alvaro Alencar14, David Lewis15, **Jennifer Woyach16, Kami Maddocks16**, Krish Patel17, 18, Yucai Wang19, Joanna Rhodes20, Constantine Tam21, John Seymour22, Hirokazu Nagai23, Julie Vose24, Bitu Fakhri25, Marc Hoffmann26, Francisco Hernandez-Ilizaliturri27, Andrew Zelenetz28, Anita Kumar28, Talha Munir29, Donald Tsai30, Paolo Abada30, Minna Balbas30, Jian Li30, Ying (denise) Wang30, Lindsey Roeker31, Toby Eyre32

Poster Presentations I

AML | Abstract #2906

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Authors: Jan-Niklas Eckardt¹, Ishan Srivastava¹, Chethan Babu², Sebastian Riechert², Tim Schmittmann², Susann Winter¹, Martin Schneider¹, Markus Badstübner², **Ann-Kathrin Eisfeld³**, Haley Roberts³, Christoph Röllig¹, Martin Bornhäuser¹, Jan Moritz Middeke¹, **Andrew Srisuwananukorn**

AML | Abstract #9467

High efficacy of azacitidine combined with lenalidomide in TP53 mutation-positive and other high-risk myelodysplastic neoplasms.

Authors: Xin Yan¹, **Chunhua Song²**, Zheng Ge ¹

AML | Abstract #9477

Residual mutations in epigenetic modifiers are associated with poor prognosis and high relapse rate in acute myeloid leukemia

Authors: Xin Yan¹, **Chunhua Song²**, Zheng Ge ¹

AML | Abstract 12039

Treatment responses and survival of newly diagnosed older or unfit patients with IDH1/2-mutated acute myeloid leukemia: an analysis of the MARROW consortium

Authors: Onyee Chan ¹ , Michael Walker², Deedra Nicolet², Krzysztof Mrózek², Najla Al Ali¹, Christine McMahon³, Jesus Gonzalez-Lugo⁴, Joshua Zeidner⁵, Brittany Ragon⁶, Charles Foucar⁷, Yazan Madanat⁸, Kieran Sahasrabudhe⁹, Bianca Barredo⁹, Lauren Banaszak⁹, Andres Gomez-De Leon¹⁰, Michael Hochman¹¹, Douglas Tremblay¹², Michael Haddadin¹³, Tara Lin⁴, Jeffrey Lancet¹, Rami Komrokji¹, Elaine Mardis², Alex Ambinder¹⁴, Alice Mims², **Ann-Kathrin Eisfeld²**

AML | Abstract #12085

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia

Authors: **Maria Velegraki ¹** , Cankun Wang^{1, 2}, Deedra Nicolet³, Maryam Soltani-asl¹, Samantha Teierle⁴, Michael Walker³, Justice Ameyi³, Gaurav Shrestha¹, Kelsi Reynolds¹, Krzysztof Mrózek³, Payton Weltge¹, Ethan Hamp³, Jill Buss³, Andrea Laganson³, Jordan Krull^{1, 2}, John Byrd⁵, Richard Stone⁶, Cecelia Miller⁷, Qin Ma¹, **Ann-Kathrin Eisfeld³**, Zihai Li¹

AML | Abstract #13899

Accounting for long-term survivors and population-expected survival improves survival outcomes estimation and prediction in older patients with core-binding factor Acute Myeloid Leukemia

Authors: *Justice Ameyi* 1, 2, *Deedra Nicolet*1, *Michael Walker*1, *Krzysztof Mrózek*1, ***Ann-Kathrin Eisfeld***1, *Kellie Archer*2

AML | Abstract #14200

The bromodomain and extra-terminal domain protein BRD4 promotes both self renewal and inflammation in TET2 mutated clonal hematopoiesis

Authors: *Alexander Marr*1, *Madeline Halpin*2, *Dominique Corbin*1, *Britten Gordon*1, *Somi Benrashid*1, *Ethan Whipp*2, *Mehdi Gharghabi*2, *Jean Truxall*1, *Olivia Cahn*1, *Rathan Kumar*1, ***Parvarthi Ranganathan***1, ***Bethany Mundy-Bosse***1, ***Jennifer Woyach***1, *Julia Cooper*3, ***Marina Beltrami Moreira***1, ***Jayanshu Jain***1, ***James Blachly***1, ***Uma Borate***1, ***Rosa Lapalombella***1, ***Nicole Grieselhuber*** 1

BMT-CT | Abstract #11153

Pre-HCT creatinine defines sex-specific risk for severe TMA after allogeneic transplantation: A report from the MIDAS consortium

Authors: *Theresa Hahn* 1 , *Nelli Bejanyan*2, ***Qihong Zhao***3, ***Elizabeth Miller***3, ***Patrick Elder***3, *Shernan Holtan*1, *Lucy Langenberg*4, *Lotus Neidemire-Colley*3, ***Parvarthi Ranganathan***3, *Stella M Davies*4, ***Sumithira Vasu***3

BMT-CT | Abstract #11465

Artificial intelligence system for delivering interactive and verifiable guideline-based clinical decision support in hematology

Authors: ***Jiasheng Wang*** 1 , *Kirti Arora*2, *David Swoboda*3, *Aziz Nazha*4

BMT-CT | Abstract 13534

A novel DLL4 enhancer regulates sinusoidal niche-mediated HSC proliferation and maintenance

Authors: *Wantong Li* 1 , *Konur Oyman*1, *Annika Chura*1, *Shelby Cabrera*1, *Raegan Wood*1, ***Bradley Blaser***

CLL | Abstract 1686

A phase II multi-institutional study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Authors: ***Aseel Alsouqi*** 1 , ***Ying Huang***1, *Lindsey Rike*1, *Lillian Dweik*1, *Swetha Hinton*1, *Mollie Moran*1, *Mark Reid*1, *Corinne Hoffman*1, *Cara Grantier*1, *Margaret Lucas*1, ***Amneet Bajwa***1, ***Seema Bhat***1, ***Michael Grever***1, ***Kerry Rogers***1, *Harsh Shah*2, ***Jennifer Woyach***1, *Adam Kittai*3

CLL | Abstract #4221

Venetoclax enhances T cell fitness and CAR T-Cell manufacturing potential in chronic lymphocytic leukemia (CLL)

Authors: Arun Arunachalam 1, 2, Beatriz Coutinho De Oliveira1, 2, Celine Gregoire1, 2, Ziran Zhao1, 2, Lily SimpsonHeavey3, John Molina4, Arnon Kater5, Fleur Peters5, Adrian Wiestner6, **Jennifer Woyach**7, J. Joseph Melenhorst1, 2

CLL | Abstract #7483

Pirtobrutinib in post-CBTKI CLL/SLL: Final update from the Phase 1/2 BRUIN Study with more Than 5 Years Follow-Up

Authors: William Wierda 1, Jennifer Brown2, Paolo Ghia3, 4, Lindsey Roeker5, Krish Patel6, Toby Eyre7, Talha Munir8, Ewa Lech-Maranda9, Nicole Lamanna10, Constantine Tam11, John Seymour12, Benoit Tessoulin13, Nirav Shah14, Chaitra Ujjani15, Bita Fakhri16, Catherine Coombs17, Ian Flinn18, Manish Patel19, Sunita Dwivedy Nasta20, Jonathon Cohen21, Alvaro Alencar22, Chan Cheah23, Shuo Ma24, Joanna Rhodes25, Deepa Jagadeesh26, Pier Luigi Zinzani27, Anders Österborg28, Koji Izutsu29, Noriko Fukuhara30, Donald Tsai31, Paolo Abada31, Minna Balbas31, Jian Li31, Ying (denise) Wang31, Wojciech Jurczak32, **Jennifer Woyach**

CLL | Abstract 11446

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Authors: **Britten Gordon** 1, Lillian Cool1, Elizabeth Muhowski1, Lianbo Yu1, Janani Ravikrishnan1, Samon Benrashid1, Andrew Mitchell1, Alexander He1, Shrilekha Misra1, Tzung-Huei Lai1, Shanmugapriya Thangavadivel1, Alexander Marr1, Jazmin Urrutia1, Casey Leimbach1, Naina Karnati1, Serena Li Zhao1, Sonam Sonam1, Smita Kumari1, Elizabeth Perry1, **Kerry Rogers**1, Adam Kittai2, **Seema Bhat**1, **Aseel Alsouqi**1, **Natarajan Muthusamy**1, John Byrd3, Deepa Sampath4, **Rosa Lapalombella**1, Blake Peterson1, Yi Chen5, Stephen Anthony5, Yu Chen5, **Jennifer Woyach**

CLL | Abstract 13682

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

Authors: Anthony Mansour1, **Ying Huang**1, Samon Benrashid1, Samantha Teierle1, Sydney Fobare1, Shrilekha Misra1, **Aseel Alsouqi**1, **Michael Grever**1, Gerard Lozanski1, Matthew Avenarius1, Joie Olayiwola1, Mollie Moran1, Margaret Lucas1, Swetha Hinton1, Cara Grantier1, Corinne Hoffman1, Mark Reid1, **Kerry Rogers**1, **Seema Bhat**1, **Jennifer Woyach** 1, Cecelia Miller1

CML | Abstract 2835

Treatment Cost per Adverse Event Symptom-Free Day of Asciminib and Second-Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Authors: **Jennifer Vaughn** 1, Nadine Zawadzki², Caroline Hardy³, Gabriel Marquez⁴, Gopi Madhav Bommidi⁵, Poornima Sachin Dhobe⁵, Sai Vasmi Gedala⁵, Islam Mohamad Sadek⁶, Jason Shafrin², David Wei⁶

CML | 4348

Expert Consensus on the Clinical Management of Congenital Thrombotic Thrombocytopenic Purpura in Asia-Pacific: A Modified Delphi Panel

Authors: Hyoung Jin Kang¹, Fernanda Orsi², **Spero Cataland** 3, Jerzy Windyga⁴

CML | Abstract #11116

Comparative Impact of Tyrosine Kinase Inhibitor Dose-Reduction on Ability to Achieve Treatment-Free Remission Among TKI-Intolerant Patients with Chronic Myeloid Leukemia

Authors: Melanie Rebechi 1, **Nidhi Sharma**¹, Audrey Propp¹, **Qihong Zhao**¹, Michael Marcucci¹, Allyson Waller¹, Marvellous Olowookere¹, Alyssa Swank¹, Christian Hu¹, **Alice Mims**¹, **Jennifer Vaughn**¹

GVHD | Abstract #8755

Grade I Acute Graft-Versus-Host Disease: Treat or Not?

Authors: Yu Akahoshi 1, Nikolaos Katsivelos¹, Ioannis Evangelos Louloudis¹, Daniela Weber², Francis Ayuk³, William Hogan⁴, Yi-Bin Chen⁵, Aaron Etra¹, Paibel Aguayo-Hiraldo⁶, Chantiya Chanswangphuwana⁷, **Hannah Choe**⁸, Elizabeth Hexner⁹, Carrie Kitko¹⁰, Monzr M. Al Malki¹¹, Pietro Merli¹², Timothy Olson¹³, Muna Qayed¹⁴, Ingrid Vasova¹⁵, Matthias Woelfl¹⁶, Janna Baez¹, Gilbert Eng¹, Sigrun Gleich², George Morales¹, Nikolaos Spyrou¹, Rachel Young¹, Ryotaro Nakamura¹¹, James Ferrara¹, John Levine

GVHD | Abstract #9017

Anti-Inflammatory Drug Pegtarazimod (RLS-0071) Demonstrates Clinical Improvement in Lower Gastrointestinal Acute Graft-Versus-Host Disease and Target Engagement of Key Inflammatory Marker Myeloperoxidase

Authors: Robert Zeiser 1, **Hannah Choe**², José Antonio Pérez-Simón³, Kenji Cunnion⁴, Monzr M. Al Malki⁵

Lymphoma | 2175

Comparison of Real-World Survival Outcomes and Time Toxicity of CAR T-Cell Versus Bispecific Antibody Therapies in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort from 15 US Academic Institutions

Authors: Ajay Major 1, 2, Diana Abbott^{1, 2}, Jordan Snyder³, Nausheen Ahmed³, Alline Amorim⁴, Jose Villasboas Bisneto⁴, **John Sharp**⁵, **Timothy Voorhees**⁵, Samin Houshyar⁶,

Danielle Wallace⁶, Arjab Adhikari⁷, Dilan Patel⁷, Christopher Wanjiku⁸, Charlotte Wagner⁹, Allison Bock⁹, Taylor Brooks¹⁰, Haya Al Any¹¹, Mazie Tsang¹¹, Mohamed Rajab¹², Madiha Iqbal¹², Nidhi Desai¹³, Supriya Gupta¹³, Nicole Altomare¹⁴, Reem Karmali¹⁴, Daniel Trotier¹⁵, Priyanka Pophali¹⁵, Edd Ricker¹⁶, Hua-Jay Cherng¹⁶, Arjun Gupta¹³, Brian Hill¹⁰

Lymphoma | 4487

Assessment of EBV DNA Methylation to Guide Antiviral Use in EBV-Associated Lymphoma

Authors: *Cara Noel^{1, 2}, Christoph Weigel^{1, 3}, Haley Klimaszewski^{1, 2}, Kurtis Host^{1, 3}, Yue-Zhong Wu^{1, 3}, Sarah Schlotter^{1, 3}, Elshafa Ahmed^{1, 3}, Eric Brooks³, **James Blachly^{1, 3, 4}**, Mark Lustberg⁵, **Timothy Voorhees^{1, 3}**, **Christopher Oakes^{1, 3, 4}**, **Robert Baiocchi^{1, 3}***

Lymphoma | Abstract #7096

Multiparametric Integration Improves Diagnostic Categorisation of Mature, Non-CLL B-Cell Leukemias Including Atypical CLL – Results from the Prospective Enable-NGS Study

Authors: *Li Yuan Chan¹, Matthew Cross¹, Grzegorz Pietka², Kyoko Yamaguchi³, Sarah Dunne¹, Leonora Conneely¹, Elise Nash¹, Michael Hubank², Mikel Valganon-Petrizan², Farheen Mir⁴, Michelle Furtado⁵, Gwynn Matthias⁶, Pawel Kaczmarek⁷, Sarah Lawless⁸, Siamak Arami⁹, Sangeeta Atwal¹⁰, Elisabeth Grey-Davies¹¹, Sofia Galli¹², Betty Cheung¹³, Sudhakaran Makkuni¹⁴, Andrew Wotherspoon¹, Ayoma Attygalle¹, Simon O'Connor¹, David Taussig¹, Dima El-Sharkawi¹, Claire Dearden¹⁵, Kabir Mohammed¹⁶, Alan Dunlop¹⁶, Ricardo Morilla¹⁷, Karol Pal^{18, 19}, Nikos Darzentas¹⁸, **Christopher Oakes³**, David Gonzalez²⁰, Dorte Wren¹, Sunil Iyengar¹*

Lymphoma | Abstract #8253

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma and Multicentric Castleman Disease

Authors: *Jose Mercado-Matos¹, Irene Ekwede¹, Margaret Namubiru¹, Ijeoma Agwu¹, Anaida Widell¹, Robert Yarchoan¹, Ramya Ramaswami¹, **Kathryn Lurain^{1, 2}***

Lymphoma | Abstract #8920

Subgroup Analysis Based on Prior Treatment from the Phase 3 Allele Study of Tabelecleucel for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease

Authors: *Sarah Nikiforow¹, Kris Mahadeo², Sridhar Chaganti³, Amer Beitinjaneh⁴, Sylvain Choquet⁵, Daan Dierickx⁶, Armin Ghobadi⁷, Roberta Valenti⁸, Anke Friedetzky⁹, Sandrine Roye⁹, Ran Reshef¹⁰, Susan Prockop¹¹, **Robert Baiocchi¹²***

Lymphoma | Abstract #9124

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Patients with Non-Hodgkin's Lymphoma and Concurrent Autoimmune Disease

Authors: ***Zachary Braunstein¹**, Eric McLaughlin², **Timothy Voorhees¹**, **Jiasheng Wang¹**, Evandro Bezerra¹, **David Bond¹**, **Audrey Sigmund¹**, **Robert Baiocchi¹**, **Yun Choi¹**, **John***

Reneau1, Yazeed Sawalha1, Kami Maddocks1, Walter Hanel1, Lapo Alinari1, Beth Christian1, Kerry Rogers1, Seema Bhat1, Jisna Paul3, Ali Ajam3, Judith Lin3, Gabriela Sanchez-Petitto1, Polina Shindiapina1, Sarah Wall1, Jennifer Woyach1, Wael Jarjour3, Sumithira Vasu1, Marcos de Lima1, Jonathan Brammer1, Alexa Meara2, Nathan Denlinger1

Lymphoma | Abstract #9281

A Retrospective Multi-Center Review of the Safety and Efficacy of Bispecific T-Cell Engagers in the Management of Post-Transplant Lymphoproliferative Disorder – The BITE PTLD Study

Authors: *Nikita Dave 1, Imran Nizamuddin2, Neha Mehta-Shah2, Edd Ricker3, Jennifer Amengual3, Robert Baiocchi4, Timothy Voorhees4, Stefan Barta1, 5, Jordan Carter1, 5, Elise Chong1, 5, Michael Cook1, 5, Daniel Landsburg1, 5, Stephen Schuster1, 5, Colin Thomas1, 5, Emily Tomasulo1, 5, Jakub Svoboda1, 5, Sunita Dwivedy Nasta1, 5*

Lymphoma | Abstract #9282

PRMT5 Is a Therapeutic Vulnerability in Cutaneous T-Cell Lymphoma

Authors: *Nicole Peterman 1, Pushpa Lata1, Christoph Weigel1, Sydney Leon1, Ian Hout1, Wing Chan1, Ronny Schmidt2, Ha Tran3, Youssef Youssef1, Peg1532gy Scherle4, Neha Bhagwat4, John Reneau1, Catherine Chung1, Jonathan Brammer1, Ryan Wilcox5, Lapo Alinari1, Robert Baiocchi1, Walter Hanel1*

Lymphoma | #10429

Safety and Immunomodulatory Effects of Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Final Phase I Trial Results

Authors: *Nathan Denlinger 1, NoJoon Song2, Negin Goodarzi2, Rina Welkie3, Jungmin Shin2, Jordan Krull2, Kathleen McConnell1, Narendranath Epperla4, Jonathan Brammer1, Yazeed Sawalha1, David Bond1, Evandro Bezerra1, John Reneau1, Audrey Sigmund1, Yun Choi1, Walter Hanel1, Lapo Alinari1, Polina Shindiapina1, Gabriela Sanchez-Petitto1, Hannah Choe1, Sarah Wall1, Jiasheng Weng1, Chelsea Steiner1, Xiaopei Huang1, Beth Christian1, Sam Penza1, Robert Baiocchi1, Kami Maddocks1, Samantha Jaglowski5, Sumithira Vasu1, Qin Ma2, Dongjun Chung2, Mark P Rubinstein2, Zihai Li2, Marcos de Lima1, Paolo Caimi6, Timothy Voorhees1*

Lymphoma | Abstract #11797

Identification of an Optimal Absolute Lymphocyte Count Before Bispecific Antibody Therapy for Large B-Cell Lymphoma: A Collaborative US Bispecific Consortium Study

Authors: *Kunhwa Kim 1, Zhouxuan Li2, Wei Qiao2, Amy Ayers3, Zachary Hunzeker1, Allison Bock4, Ayushi Chauhan3, Lorenzo Falchi5, Reid Merryman6, Swetha Thiruvengadam7, Andrew Jallouk8, Omnia Farahat1, Steven Bair9, Matthew Lunning10, Shakthi Bhaskar8, Yazeed Sawalha11, Jennifer Crombie6, Narendranath Epperla4, Geoffrey Shouse7, Sairah Ahmed3, Paolo Strati3, Ajay Major9*

Lymphoma | Abstract #14746

Daratumumab with Dose-Adjusted EPOCH Feasibility and Early Efficacy in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Authors: *Ariela Noy 1 , Stefan Barta2, Grace Van Hyfte3, Deukwoo Kwon4, **Robert Baiocchi5**, Juan Carlos Ramos6, Paul Rubinstein7, Amy Chadburn8, Richard Ambinder9*

Lymphoma | Abstract #14955

Real World Outcomes of Sequencing Bispecific Antibodies in Patients with Relapsed / Refractory Follicular Lymphoma: A Multi-Center Cohort Study from Cubic Consortium

Authors: *Chijioke Nze 1 , Allison Bock2, Yizhe Xu2, Yuxin Zhao2, Amy Ayers1, Lorenzo Falchi3, Reid Merryman4, Steven Bair5, Ajay Major5, Andrew Jallouk6, Swetha Thiruvengadam7, Christopher D'Angelo8, Matthew Lunning8, Shakthi Bhaskar6, **Yazeed Sawalha9**, Omnia Farahat1, Ayushi Chauhan1, Geoffrey Shouse7, Jennifer Crombie4, Alex Herrera7, Gilles Salles3, Christopher Flowers1, Sairah Ahmed1, Narendranath Epperla2*

Sunday, December 7

SPECIAL INTEREST SESSION/ EDUCATION SESSION

2:05 p.m. Plenary Introducer: TBA

Kerry Rogers, MD

4:30 p.m. Speaker: Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics? Molecular Approach to Cytopenia and Bone Marrow Failure

Uma Borate, MD, MSc

ORAL PRESENTATIONS:

9:45 AM

Lymphoma | Abstract #11119

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Authors: *Reid Merryman 1 , Danielle Wallace2, Robert Redd1, Heather Walker1, Rafaella Tringale1, Vanessa Kats1, Siri Sagedahl1, Ioulia Vogiatzi1, Mingzeng Zhang1, Emily Sumpena1, Weihsin Chuan1, **Audrey Sigmund3**, Inhye Ahn1, Amy Bessnow1, Jennifer R. Brown1, Jennifer Crombie1, Matthew S Davids1, David Fisher1, Cynthia Hahn1, Eric Jacobsen1, Caron Jacobson1, Austin Kim1, Ann LaCasce1, Oreofe Odejide1, Erin Parry1, David Qualls1, Christine Ryan1, Aswin Sekar1, Sumana Devata4, Carla Casulo2, **Kami Maddocks3**, Mark Murakami1, Philippe Armand1, **Yazeed Sawalha***

MPN | Abstract # 3882

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Authors: John Mascarenhas¹, Joseph Scandura², Vikas Gupta³, Kazuya Shimoda⁴, James McCloskey⁵, Firas El Chaer⁶, Prithviraj Bose⁷, Raajit Rampal⁸, **Andrew Srisuwananukorn⁹**, Timothy Devos¹⁰, Ruben Mesa¹¹, Professor Francesco Passamonti¹², Srinivas Tantravahi¹³, David Ross¹⁴, Lindsay Rein¹⁵, Jean-Jacques Kiladjian¹⁶, Takanori Teshima¹⁷, Takuji Yamauchi¹⁸, Noboru Asada¹⁹, Anna Halpern^{20, 21}, Tamanna Haque⁸, Etienne Paubelle²², Noriko Fukuhara²³, Pankit Vachhani²⁴, Michiko Ichii²⁵, Ronald Hoffman¹, Marcello Rotta²⁶, Michael Keng²⁷, Stefan Wickenhauser²⁸, Karen Ansaldo²⁹, Masataka Seki²⁹, Jinny Lee²⁹, Vincent Loksa²⁹, Zhonggai Li²⁹, Jason Foulks²⁹, Sujun Kabir²⁹, Jatin Shah²⁹, Claire Harrison³⁰

10 a.m.

AML | Abstract #2270

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Authors: Curtis Lachowicz¹, Andy Kaempf¹, Jad Othman^{2, 3, 4}, Seongseok Yun⁵, Mael Heiblig⁶, Michael Heuser^{7, 8}, Rabia Shahswar⁷, Anand Patel⁹, Rafael Madero-Marroquin⁹, Joseph Cannova⁹, Irene Zacheo¹⁰, Federica Monaco¹¹, Dimitrios Drekolias⁵, Fatima Tuz Zahra⁵, Amine Belhabri¹², Urbain Tauveron-Jalenques¹³, Emmanuelle Tavernier¹⁴, Martin Carre¹⁵, Gaspar Aspas Requena¹⁶, Nicola Long¹, Rachel Cook¹, Elie Traer¹, Ronan Swords¹, Jennifer Saultz¹, Jenny O'Nions¹⁷, Faisal Basheer¹⁸, John Laurie¹⁹, **Shivani Handa²⁰**, Eytan Stein²¹, Maria Baer²², Wendy Stock⁹, Rebecca Olin²³, William Blum²⁴, Gary Schiller²⁵, Tara Lin²⁶, Emily Curran²⁷, **Ying Huang²⁸**, **Rina Welkie²⁰**, Ashley Yocum²⁹, Giovanni Marconi³⁰, Ellen Madarang³¹, Justin Watts³¹, Yazan Madanat³², Richard Dillon³³, Sanam Loghavi³⁴, Joshua Zeidner³⁵, Daniel Pollyea³⁶, Elsa Bernard^{37, 38}

12 p.m.

Lymphoma | Abstract #11036

Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis

Authors: **Chunhua Song¹**, Benjamin Kaffenberger^{1, 2}, Chelsea Steiner¹, Dayong Wu¹, Yi Zhang¹, **Xiaopei Huang¹**, Yiping Yang Read abstract #11036:

12:30 p.m.

CH | Abstract #11349

A diagnostic hematology clinic pilot program: Increasing access and optimizing resources

Authors: **Kathryn Knisely¹**, **Marina Beltrami Moreira²**, **Roberta Azbell²**, Lindsay Hunter¹, Christine Harsh¹, Tina Sowers¹, Raquel Reinbolt¹, Samantha Knight¹, Rupa Ghosh-Berkebile¹, Victoria Krogg¹, **Spero Cataland²**, **Regina Crawford²**, **Sherraine Della-Moretta²**, **Nicolas Gallastegui-Crestani²**, **Jennifer Vaughn²**

4:30 p.m.

BMT-CT | Abstract #7393

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Authors: *Matthew Frank 1 , David Qualls2, Armin Ghobadi3, Jordan Gauthier4, Michael Tees5, Luke Mountjoy5, Joseph McGuirk6, Sattva Neelapu7, Reem Karmali8, Iris Isufi9, Brian Hill10, Craig Sauter10, Catherine Diefenbach11, Jay Spiegel12, Lizamarie Bachier-Rodriguez13, Monalisa Ghosh14, Nirav Shah15, Rahul Lakhota16, Francisco Hernandez-Ilizaliturri17, Anuja Abhyankar17, Elise Chong18, Matthew Schwede19, Krish Patel19, Olalekan Oluwole20, John Baird21, **Nathan Denlinger22**, Farrukh Awan23, Michael Jain24, John Timmerman25, Cesar Sanchez26, Muthu Kumaran26, Jean Yared27, Jon Arnason28, Ishan Tatake28, Usama Gergis29, Peter Riedell30, Keith Pratz2, Nirali Shah16*

5:30 p.m.

CLL | Abstract 2587

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Authors: **Jennifer Woyach 1** , Luguí Qiu2, Sebastian Grosicki3, Tomasz Wrobel4, Marcelo Capra5, Jaroslaw Czyz6, Shuhua Yi2, Ki-Seong Eom7, Anna Panovská8, Wojciech Jurczak9, Kamel Laribi10, Lutz Jacobasch11, Ross Baker12, Richy Agajanian13, Alejandro Berkovits14, Muhit Özcan15, Stephane Lepretre16, Catherine Coombs17, Paula Cramer18, Katharine Lewis19, 20, Marisa Hill21, Katherine Bao21, Yuanyuan Bian21, Amy Ruppert Stark21, Ching Ching Leow21, William Wierda22

POSTER PRESENTATIONS II

AML | Abstract # 8418

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Authors: *Megan Fleming 1 , Allyson Waller1, **Subodh Bhatta2**, Pooja Kumar1, Tracelyn Freeman1, Lexus Frazier1, Nilmarie Ayala-Fontanez1, Adithya Ghantae1, Sharon Loo3, Jasmine Kainth3, **Ying Huang2**, **James Blachly4**, **Bradley Blaser4**, **Uma Borate4**, **Ann-Kathrin Eisfeld4**, **Nicole Grieselhuber4**, **Shivani Handa4**, **Jayanshu Jain1**, **Karilyn Larkin4**, **Meixiao Long4**, **Alice Mims4**, **Andrew Srisuwananukorn4**, **Gregory Behbehani4***

AML | Abstract #13339

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Authors: *Pooja Kumar 1 , Deedra Nicolet2, Tracelyn Freeman1, Lexus Frazier1, Allyson Waller1, Megan Fleming1, Michael Walker2, **Gregory Behbehani3**, **James Blachly3**, **Uma Borate3**, **Nicole Grieselhuber3**, **Shivani Handa3**, **Jayanshu Jain3**, **Karilyn Larkin3**, **Meixiao Long3**, **Ann-Kathrin Eisfeld3**, **Alice Mims***

AML | Abstract #13654

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Authors: *Tuan Phan 1 , Evandro Bezerra1, Hannah Choe1, Nathan Denlinger1, Marcos de Lima1, Sam Penza1, Gabriela Sanchez-Petitto1, Jeremy Sen2, Polina Shindiapina1, Justin Tossey2, Sumithira Vasu1, Sarah Wall1, Jiasheng Wang1* [Read Abstract #13654](#)

AML | Abstract #14739

Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Authors: *Uma Borate 1 , Jayanshu Jain1, Ying Huang1, Kaitlyn Dvorak-Kornaus1, Alexander Perl2, Joshua Zeidner3, Alice Mims1*

BMT-CT | Abstract #7675

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Authors: *Kayleigh Ingersoll Omdahl 1, 2, 3, Steven Siegel1, 2, 3, Jiayi Dong1, 2, 3, Susan DeWolf4, Kyle Hebert2, Donna Neuberg2, Isabella Schichter1, 2, 3, Alexandre Albanese1, 2, 3, Paul Keskula1, 2, 3, Lorenzo Cagnin1, 2, 3, Kristy Applegate5, Merav Bar6, Saurabh Chhabra7, Sung Choi8, William Clark9, Suman Das10, Robert Jenq11, Richard Jones12, John Levine13, Brent Logan14, Michael Martens14, Hemant Murthy15, Armin Rashidi6, Marcie Riches16, Wael Saber14, Karamjeet Sandhu11, Anthony Sung17, **Karilyn Larkin18**, Monzr M. Al Malki11, Mahasweta Gooptu2, Hany Elmariah19, 20, Amin Alousi21, Lyndsey Runaas14, Brian Shaffer4, Andrew Rezvani20, Najla El Jurdi22, 23, Alison Loren24, Mary Horowitz14, Javier Bolanos-Meade12, Shernan Holtan25, Ami Bhatt20, Miguel-Angel Perales4, Leslie Kean1, 2, 3*

BMT-CT | Abstract #11546

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

Authors: *Jiasheng Wang 1 , Tuan Phan1, Pedro Silberman2, Evandro Bezerra1, **Jonathan Brammer1, Hannah Choe1, Nathan Denlinger1, Marcos de Lima1, Sam Penza1, Gabriela Sanchez-Petitto1, Polina Shindiapina1, Sumithira Vasu1, Sarah Wall1, Reza Averly3, Xia Ning3, Bradley Blaser***

CLL | Abstract #2172

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH)

Authors: *John Allan 1 , Andrew Lipsky2, **Seema Bhat3**, Suchitra Sundaram4, Lubing Wu1, Jane Matejka1, Brittany Hobbie1, Nourhan Hamadi1, Simone Morris1, Zhengming Chen1, Ivo Sah Bander1, Madhu Ouseph1, Jia Ruan1, Amy Chadburn1, Adam Kittai4, Richard Furman*

CLL | Abstract #14931

Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Authors: *Paolo Caimi* 1 , *Leland Metheny*2, ***Lapo Alinari***3, *Changchun Deng*2, *Matthew Spear*4, *Jeff Liter*4, *Branden Moriarity*4, *Beau Webber*4, ***Jennifer Woyach***3, *Brian Hill*1, *J. Joseph Melenhorst*5

CH | Abstract #2212

Clinical management of congenital thrombotic thrombocytopenic purpura in Latin America: Expert consensus from a modified Delphi panel

Authors: *Fernanda Orsi*1, *Hyoung Jin Kang*2, *Jerzy Windyga*3, ***Spero Cataland*** 4

CH-Sickle Cell | Abstract #10138

Menstruation-induced vaso-occlusive crisis in women with sickle cell disease

Authors: ***Sherraine Della-Moretta*** 1 , ***Rina Welkie***2, *Ryan Hicks*2, *Susan Creary*3, *Robert Cronin*2, *Maya Neidhart*2

CH-Cancer and Aging | Abstract #8218

Real world experience of patient outcomes in a dedicated clonal hematopoiesis hematology clinic

Authors: ***Jayanshu Jain*** 1 , *Julia Cooper*1, *Halle Wade*1, ***Marina Beltrami Moreira***1, ***James Blachly***1, ***Nicole Grieselhuber***1, ***Bethany Mundy-Bosse***1, ***Uma Borate***1

GVHD | Abstract #7723

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Authors: *Mahasweta Gooptu*1, *Monzir M. Al Malki*2, *Stephanie Bo-Subait*3, *Brent Logan*4, 5, *Erin Leckrone*3, *Sarah Smith*3, *Heather Stefanski*3, *Jeffery Auletta*3, *Stephen Spellman*3, *Craig Malmberg*3, *Medhat Askar*3, 6, *Rachel Cusatis*5, *Farhad Khimani*7, *Dipenkumar Modi*8, *Mehdi Hamadani*5, *Martin Maiers*3, *Joseph Stanek*3, *Javier Meade*9, *Uttam Rao*10, *Jordan Milner*11, *Ramzi Abboud*12, *Katarzyna Jamieson*13, *George Carrum*14, *Bhagirathbhai Dholaria*15, *William Hogan*16, *Ran Reshef*17, *Satyajit Kosuri*18, *Rachel Cook*19, *Karen Ballen*20, *Alison Loren*21, ***Karilyn Larkin***22, *Sally Arai*23, *Muna Qayed*24, *Sung Choi*25, *Larisa Broglie*5, 26, *Bronwen Shaw*5, *Steven Devine* 3 , *Antonio Jimenez Jimenez*27, *Brian Shaffer*

GVHD | Abstract #7777

Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib

Authors: *Henry Castellani* 1 , *Jean Caputo*2, ***Qihong Zhao***2, *Justin Tossey*2, ***Marcos de Lima***2, ***Sumithira Vasu***2, ***Sarah Wall***2, ***Gabriela Sanchez-Petitto***2, *Evandro Bezerra*2, ***Hannah Choe***2

Lymphoma | Abstract #7840

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Authors: Pallawi Torka 1 , Allison Bock2, Elena Nazarenko2, Yizhe Xu2, John Vaughn3, Swetha Thiruvengadam4, Ajay Major5, Kanithra Sekaran6, Daniel Reef7, Calvin Lee8, Gordon Smilnak9, Efrat Luttwak1, Vrutti Patel10, Harsh Shah2, Andrew Ip11, Grace Baek12, Ritwick Mynam13, Dahlia Sano14, Drew Gerber15, Ayo Falade16, Marisa Palmeri17, Rudy Mrad18, Madiha Iqbal19, **John Sharp20, Timothy Voorhees20**, Praveen Ramakrishnan Geethakumari18, Joanna Rhodes17, Urshila Durani16, Hua-Jay Cherng15, Yasmin Karimi14, Priyanka Pophali13, Mengyang Di12, Tatyana Feldman11, Jakub Svoboda10, Krithika Shanmugasundaram9, Alex Niu8, Natalie Grover7, Reem Karmali6, Alex Herrera4, Catherine Diefenbach3, Narendranath Epperla2

Lymphoma | Abstract #8345

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Authors: Allison Bock 1 , Lei Feng2, Ayushi Chauhan2, Lorenzo Falchi3, Reid Merryman4, Sonia Godbole5, Swetha Thiruvengadam6, Andrew Jallouk7, Ajay Major8, Christopher D'Angelo9, Amy Ayers2, Omnia Farahat2, Steven Bair8, Matthew Lunning9, Shakthi Bhaskar7, Alex Herrera6, **Yazeed Sawalha5**, Jennifer Crombie4, Gilles Salles3, Narendranath Epperla1, Sairah Ahmed2

Lymphoma | Abstract #8897

Synergistic efficacy of EZH2 inhibitor combined with new flavonoid derivatives in AML patient-derived xenograft mouse models

Authors: JChan Yang1, Qinglong Guo 2, Hui Hui2, Hui Li2, **Chunhua Song3** , Zheng Ge1

Lymphoma | Abstract #9434

Targeting the casein kinase II /ikaros axis sensitizes TKI activity by suppression of GLUT1 expression and glycolysis in ph+ ALL

Authors: Linyao Zhang1, Qi Han1, Huimin Xiang1, **Chunhua Song 2** , Zheng Ge

Lymphoma | Abstract #9774

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Authors: Andrew Jallouk 1 , Lorenzo Falchi2, Ayushi Chauhan3, Geoffrey Shouse4, Swetha Thiruvengadam4, **Yazeed Sawalha5, Sonia Godbole5**, Ajay Major6, Reid Merryman7, Shakthi Bhaskar1, Allison Bock8, Amy Ayers3, Omnia Farahat3, Narendranath Epperla8, Jennifer Crombie7, Steven Bair6, Alex Herrera4, Christopher Flowers3, Gilles Salles2, Sairah Ahmed

Lymphoma | Abstract #10006

Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)

Authors: Paola Marra 1 , Rathan Kumar1, Charlene Mao2, Sydney Leon1, Ian Hout1, **Robert Baiocchi3, Parvarthi Ranganathan3, Polina Shindiapina**

Lymphoma | Abstract #10165

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Authors: David Qualls 1 , Andrew Jallouk2, Geoffrey Shouse3, Swetha Thiruvengadam3, Omnia Farahat4, Amy Ayers4, Ayushi Chauhan4, Reid Merryman1, Ajay Major5, **Yazeed Sawalha6**, Narendranath Epperla7, Matthew Lunning8, Shakthi Bhaskar2, Allison Bock7, Steven Bair5, Gilles Salles9, Christopher Flowers4, Alex Herrera3, Lorenzo Falchi9, Jennifer Crombie1, Lei Feng4, Sairah Ahmed4

Lymphoma | Abstract #10521

MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.

Authors: Evgeny Arons 1 , Tai Chin-Hsein1, Liu Yuelin2, Chi-Ping Day1, **Christopher Oakes3**, **Seema Bhat3**, **Michael Grever3**, **Kerry Rogers3**, Mark Raffeld4, Liqiang Xi2, Hong Zhou1, Mory Gould1, Arie Fischthal1, Isaac Shpilman1, Hao-Wei Wang1, Constance Yuan1, Cenk Sahinalp1, Robert Kreitman1

Lymphoma | Abstract #11442

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Authors: Alyssa Kassouf 1 , **Rina Welkie2**, **Yazeed Sawalha2**, **Audrey Sigmund2**, **Timothy Voorhees2**, **Yun Choi2**, **Robert Baiocchi2**, Jordan Lundberg3, Tracy Wiczer3, Tyler Everhardt3, Caitlyn Crawford3, Rebecca Evers3, Lindsay Rosen3, **Beth Christian2**, **Kami Maddocks2**, **David Bond2**

Lymphoma | Abstract #12237

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Narendranath Epperla 1 , Geoffrey Shouse2, Jess Hatfield3, Kanithra Sekaran4, Yun Choi5, Aishwarya Sannareddy6, Bryce Bowler7, Zain El-amir8, Ly Do9, Matthew Savas1, Taylor Kujawa1, Priyanka Pophali9, Yasmin Karimi8, Mengyang Di7, Praveen Ramakrishnan Geethakumari6, **Yazeed Sawalha5**, Reem Karmali4, Natalie Grover3, Adam Olszewski10

Lymphoma | Abstract #13895

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Authors: Yun Kyoung Tiger 1 , Charlotte Zuber2, Venkata Preetam Sandeep Kaduluri3, Taylor Kujawa4, Mollie Reese5, Joseph Lukowski6, Matthew Gromowsky6, Maun Baral7, Graham Wehmeyer8, Joshua Friedman8, Vidiya Srikakulapu9, Ross Terada10, Mia Willingham11, Benjamin Hane11, **Youssef Youssef12**, Michele Stanchina13, Juan Alderuccio13, **Timothy Voorhees12**, Joseph Bennett11, Marc Hoffmann11, Thomas Ollila10, Praveen Ramakrishnan Geethakumari9, Adam Kittai8, Dilan Patel7, Christopher D'Angelo6, Chris Dittus5, Narendranath Epperla4, Cole Sterling3, Andrew Evens1, Matthew Matasar1, Adam Olszewski10

MM | Abstract #14264

Bridging the rural gap: Real-world teclistamab outcomes from the u.S. midwest myeloma network

Authors: Adam Stepanovic 1 , Charles Pai2, Arun Augustine3, **Francesca Cottini2**, Timothy Schmidt3, Kevin Rakszawski4, Malini Surapaneni5, Rafat Abonour5, Kelvin Lee5, Attaya Suvannasankha6

MPN | Abstract # 14379

Ruxolitinib and interferon alfa induce superior rates of complete peripheral blood count remission compared to anagrelide in hydroxyurea-exposed essential thrombocythemia

Authors: Tripura Vithala 1, Seungyeon Lee1, Haley Roberts1, **Shivani Handa1, Jennifer Vaughn1, Sarah Wall1, Ping Zhang1, Andrew Srisuwananukorn1**

Monday, December 8

EDUCATION PROGRAMS/SPECIAL INTEREST SESSIONS

2:45 p.m. Moderator: Myeloproliferative Syndromes: Clinical and Epidemiological: Beyond JAK Inhibition - Therapeutic Innovation and Transplant Strategies in Myelofibrosis

(Session 634)

Sarah Wall, MD

ORAL PRESENTATIONS:

10:45 AM

GVHD | 10453

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/mtx gvhd prophylaxis: Results from the BMT CTN 1801 study

Authors: Steven Siegel 1 , Susan DeWolf2, Joseph Schmalz3, Nicholas Winn1, James Kaminski1, Stephanie Bien3, Catherine Sanders3, Harlan Robins3, Jillian Zavistaski1, Isabella Schichter1, Lea Steinberg1, Kristy Applegate4, Merav Bar5, Saurabh Chhabra6, Sung Choi7, William Clark8, Suman Das9, Robert Jenq10, Richard Jones11, John Levine12, Brent Logan13, Michael Martens13, Hemant Murthy14, Armin Rashidi5, Marcie Riches15, Wael Saber13, Karamjeet Sandhu10, Anthony Sung16, **Karilyn Larkin17**, Monzr M. Al Malki10, Mahasweta Gooptu18, Hany Elmariah19, Amin Alousi20, Lyndsey Runaas13, Brian Shaffer2, Andrew Rezvani21, N El Jurdi22, 23, Alison Loren24, Mary Horowitz13, Mehdi Hamadani13, Javier BolanosMeade11, Shernan Holtan25, Ami Bhatt21, Miguel-Angel Perales2, Leslie Kean1

11 a.m.

Lymphoma | Abstract #2921

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Authors: Xi Yang, Henry Dumke, Joseph Schroers-Martin, Yazeed Sawalha, Sree Lanka, Izel Okcu, Grzegorz Nowakowski, Peter Doukas, Reem Karmali, Meryl Colton, Michael Spinner, Vincenzo Pizzuti, Manali Kamdar, Olutobi Adewale, Yun Kyoung Tiger, Kelsey Baron, Allison Bock, Marcus Geer, Yasmin Karimi

11:15 a.m.

Lymphoma | Abstract #4341

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Authors: Varun Iyengar¹, Jomel Meeko Manzano², Lu Chen², Jessica Chicola¹, Michelle Okwali¹, Seth Buller², Guido Pelaez³, Vincenzo Pizzuti⁴, Ajay Major⁴, **Youssef Youssef⁵**, **Yazeed Sawalha⁵**, Danielle Wallace⁶, Monica Masterson⁶, Nicole Birrer⁷, Allison Bock⁷, Adrienne Nedved⁸, Yucai Wang⁸, Thomas Lucido⁹, Joanna Rhodes⁹, Siang Dim¹⁰, Jennifer Crombie¹⁰, Denisse Montana¹¹, Michele Stanchina¹¹, Juan Alderuccio¹¹, Alyssa Gibson¹², Peter Riedell¹², Tanim Jain¹³, Benjamin Heyman¹³, Heather Rasmussen¹⁴, Chaitra Ujjani¹⁴, Patrick Gould¹, Hua-Jay Cherng¹⁵, Ahmed Bahnasy¹⁶, Talal Hilal¹⁶, Joseph Parker¹⁷, Muhamad Alhaj Moustafa¹⁷, Stacy Pak², Christine Goth², David Russler-Germain³, Alex Herrera², Swetha Thiruvengadam², Pallawi Torka¹

11:45 a.m.

CLL | Abstract #2882

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Authors: Jennifer Huang, Jenna Voutsinas, Niranjana Khair, Vincenzo Pizzuti, Leyla Shune, Matthew Lei, Rodrigo Fonseca, Mohammad Ammad Ud Din, Alan Skarbnik, Agrima Mian, Sushma Bharadwaj, Aseel Alsouqi, Bret Wankel, Graham Wehmeyer, Joseph Lukowski, Alexey Danilov, Tanya Siddiqi, Meghan Thompson, Michael Scordo, Stephanie Franco, Deborah Stephens, Chaitra Ujjani, Ryan Lynch, Jordan Gauthier, William Wierda, Paul Barr, Adam Kittai, Jonah Shulman, Matthew Lunning, Kerry Rogers, Bitu Fakhri, Brian Hill, Javier Pinilla-Ibarz, Talal Hilal, Jacob Soumerai, Manali Kamdar, Qian Wu, Nitin Jain, Mazhar Shadman

2:45 p.m.

CH | Abstract #2343

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Authors: Rebecca Leaf^{1, 2}, Jodi Mones³, Tushar Shenoy⁴, Mohamed Warsame⁵, **Marina Beltrami Moreira⁶**, Sandhya Panch⁷, Andrew Leavitt^{8, 9}, Rebecca Zon^{2, 10}, Ellen Kendall¹, Sahar Shahamatdar¹, Tristan Lim¹, Can Cui¹, Debbie Jiang^{1, 2}, Sarah Kaunfer⁴, Lavanya Durai⁴, Julie-Alexia Dias⁴, Carrie Sha^{3, 11}, Aaron Holmes^{11, 12}, Neela Easwar^{3, 11}, Elizabeth Corley^{3, 11}, Ethan Zhao¹¹, Xingyi Li^{3, 11}, Amy Spelman¹³, Christina Amos¹⁴, Doris Soebbing¹³, Maria Shabih¹⁴, Trevor Jamieson¹⁴, Bolun Liu¹⁵, Guleid Hussein¹⁵, Sumeet Yadav¹⁵, Mohamed

Elsaid16, Dwight Owen17, Alexa Meara18, Patrick Juras19, Arvind Suresh8, Marina Hessel8, Jennifer Huang7, Ilya Glezerman3, Ronald Go20, Kerry Reynolds1, 2, Hanny Al-Samkari1, 2, Michael Kroll14, David Leaf

2:45 p.m.

MPN | Abstract #1549

Safety and efficacy of bromodomain and extra-terminal protein inhibitor INCB057643 monotherapy in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A phase 1 study

*Authors: Pankit Vachhani 1, Justin Watts2, Alessandro Vannucchi3, Anthony Hunter4, Srinivas Tantravahi5, Vikas Gupta6, Alessandra Iurlo7, **Andrew Srisuwananukorn8**, María Teresa Gómez Casares9, Alessandro Lucchesi10, Brandon McMahon11, Brandi Reeves12, Shireen Sirhan13, 14, 15, Blanca Xicoy16, Jun Choi17, Anna Halpern18, 19, Ellen Ritchie20, Taizo Shimomura21, Yanhong Tong22, Akihiro Tomita23, Junichiro Yuda24, Manti Guha25, Lea Burke25, Feng Zhou25, Fred Zheng25, Prithviraj Bose26*

2:45 p.m.

BMT- CT | Abstract #7144

CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC)

*Stefan Barta 1, Ariela Noy2, Kwang Woo Ahn3, Jinalben Patel3, Tiffany Hunt3, Uroosa Ibrahim4, **Robert Baiocchi5**, Deukwoo Kwon4, Marcelo Pasquini3, Richard Ambinder*

3 p.m.

CH | Abstract #7661

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

*Authors: Marie Scully 1, Paul Coppo2, Masanori Matsumoto3, **Spero Cataland4**, Thomas Ortel5, Jerzy Windyga6, Paul Knoebl7, Karim Kentouche8, Ana Antun9, Claire Dossier10, Nathalie Biebuyck11, Wolf-Achim Hassenpflug12, Sami Ibrahim13, Masataka Ishimura14, Indranil Bhattacharya15, Shan Xiao15, Kayode Badejo15, Bjorn Mellgard15, Dorothy Romanus15, Linda Wang15, Pinghai Zhang15, Tara Robinson15*

3 p.m.

Lymphoma | Abstract #15351

Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine

*Authors: **Jonathan Brammer 1, Zachary Braunstein1, 1**, Patrick Stevens1, Zachary Hutchins2, Giulia Calabretto2, Soprina Guarneri2, Eric McLaughlin1, Amy Boles2, John Reneau1, Walter Hanel1, Enrica Marchi3, Maciej Pietrzak1, Anjali Mishra2*

3:15 p.m.

CH | Abstract #5938

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Authors: Marie Scully, Spero Cataland, Paul Coppo, Paul Knoebl, Paul Brinkkoetter, Javier de la Rubia, Marielle Klein Hesselink, Josefin-Beate Holz, Flora Peyvandi

3:30 p.m.

Lymphoma | Abstract #8291

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Authors: *Amanda Chron*^{1, 2}, *Kelsey Baron*³, *Ashlee Joseph*¹, *Ayushi Chauhan*⁴, ***Sonia Godbole***⁵, *Andrew Jallouk*⁶, *Amy Ayers*⁴, *Ajay Major*⁷, *Swetha Thiruvengadam*⁸, *Narendranath Epperla*³, *Shakthi Bhaskar*⁶, *Alex Herrera*⁸, ***Yazeed Sawalha***⁵, *Sairah Ahmed*⁴, *Gilles Salles*¹, *Lorenzo Falchi*¹, *Allison Bock*³

3:45 p.m.

AML | Abstract #8236

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Authors: *Amir Fathi*¹, *Alexander Perl*², *Geoffrey Fell*³, *Brian Jonas*⁴, *Brittany Ragon*⁵, ***Alice Mims***⁶, ***Uma Borate***⁶, *Gabriel Mannis*⁷, *Karen Quillen*⁸, *Max Stahl*^{3, 9}, *Paul Koller*¹⁰, *Andrew Artz*¹⁰, *Monzr M. Al Malki*¹⁰, *Guido Marcucci*¹⁰, *Mary Linton Peters*⁸, *Timothy Graubert*¹, *Peter Westervelt*^{11, 12}, *Philip Amrein*¹, *Hanno Hock*¹, *Andrew Brunner*¹, *Gabriela Hobbs*¹, *Rupa Narayan*¹, *Michelle Lee*¹, *Brandon Aubrey*¹, *Alyssa Watson*¹¹, *Richard Hao*¹¹, *Shilton Dhaver*¹¹, *Michael Grunwald*⁵, *Yi-Bin Chen*¹, *Andrew Matthews*², *Christopher Hourigan*¹³, *Brent Wood*¹⁴, *Donna Neuberg*³, *Areej El-Jawahri*¹, *Ibrahim Aldoss*

4 p.m.

GVHD | Abstract #7189

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Authors: *Monzr M. Al Malki*¹, *Stephanie Bo-Subait*², *Brent Logan*^{3, 4}, *Sarah Smith*², *Erin Leckrone*², *Heather Stefanski*², *Jeffery Auletta*², *Stephen Spellman*², *Craig Malmberg*², *Medhat Askar*^{2, 5}, *Rachel Cusatis*⁴, *Brian Shaffer*⁶, *Dipenkumar Modi*⁷, *Farhad Khimani*⁸, *Mahasweta Gooptu*⁹, *Mehdi Hamadani*⁴, *Martin Maier*², *Joseph Stanek*², *Javier Meade*¹⁰, *Uttam Rao*¹¹, *Jordan Milner*¹², *Ramzi Abboud*¹³, *Katarzyna Jamieson*¹⁴, *George Carrum*¹⁵, *Bhagirathbhai Dholaria*¹⁶, *William Hogan*¹⁷, *Ran Reshef*¹⁸, *Satyajit Kosuri*¹⁹, *Rachel Cook*²⁰, *Karen Ballen*²¹, *Alison Loren*²², ***Karilyn Larkin***²³, *Sally Arai*²⁴, *Muna Qayed*²⁵, *Sung Choi*²⁶, *Larisa Broglie*^{4, 27}, *Bronwen Shaw*⁴, *Steven Devine*², *Antonio Jimenez Jimenez*²⁸

4:30 p.m.

BMT-CT | Abstract #1693

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Authors: Mark Levis 1 , Mehdi Hamadani2, Brent Logan2, Richard Jones1, Anurag Singh3, Mark Litzow4, John Wingard5, Esperanza Papadopoulos6, Alexander Perl7, Robert Soiffer8, Celalettin Ustun9, Masumi Ueda Oshima10, Geoffrey Uy11, Edmund Waller12, **Sumithira Vasu13**, Melhem Solh14, Asmita Mishra15, Lori Muffly16, Heeje Kim17, Matthias Stelljes18, Yuho Najima19, Masahiro Onozawa20, Kirsty Thomson21, Caroline Chen22, Nahla Hasabou22, Mathew Rosales22, Jason Hill22, Stanley Gill22, Rishita Nuthethi22, Denise King23, Adam Mendizabal23, Steven Devine24, Mary Horowitz2, Yi-Bin Chen

5 p.m.

Lymphoma | Abstract #9193

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Authors: Jing-Zhou Hou 1 , Tae Min Kim2, Seok-Goo Cho3, Sameh Gaballa4, Ranjit Nair5, Koji Izutsu6, Sumana Devata7, Dok Hyun Yoon8, Won-Seog Kim9, **Yazeed Sawalha10**, Ryan Jacobs11, Eliza Hawkes12, Ming-Chung Wang13, Constantine Tam14, Don Stevens15, Hisayuki Yokoyama16, Jin Seok Kim17, Matthew Matasar18, Aravind Ramakrishnan19, Denise Brennan20, David Sermer21, Robin Lesley22, Mihail Obrocea23, Dai Maruyama

5:15 p.m.

Lymphoma | 1972

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Authors: **Zachary Braunstein 1** , Eric McLaughlin2, Prasanth Lingamaneni3, Stefan Barta4, Miao Cao4, Tiffany Chang5, Nivetha Ganesan5, Tanaya Shree6, Binh Luu6, Neha Mehta-Shah7, Marcus Watkins7, Jasmine Zain8, Pamela Allen9, Darina Paulino9, Brittany Adams9, Jie Wang10, Amber Feng10, Enrica Marchi11, Nathan Roberts11, Ryan Wilcox12, Marc Gutierrez12, Zachary Frosch13, Tammarah Sklarz13, Tarsheen Sethi14, Francine Foss14, Anne Beaven15, Bradley Haverkos16, Rachel Treitman16, Timothy Oh17, Jonathan Moreira17, Sean Reilly18, Alan Khoo18, Pierluigi Porcu18, Abhishek Kataria19, Deepa Jagadeesh19, Alexander Carlson20, Saurabh Rajguru20, Abida Babu21, Xiaohui Zhang21, Anjali Mishra18, Robert Stuver5, Christina Poh22, Paul Hampel3, **Jonathan Brammer1**

5:30 p.m.

AML | Abstract #8754

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Authors: Fieke Hoff 1 , Alexander Li2, **Ying Huang3**, **Rina Welkie3**, Ronan Swords4, Elie Traer4, Eytan Stein5, Tara Lin6, Maria Baer7, Vu Duong7, William Blum8, Martha Arellano8, Wendy Stock9, Olatoyosi Odenike9, Joshua Zeidner10, Rebecca Olin11, Catherine Smith11, Gary Schiller12, Emily Curran13, **Shivani Handa3**, Nyla Heerema3, Timothy Chen3, Molly Martycz3,

*Mona Stefanos³, Sonja Marcus¹⁴, Leonard Rosenberg¹⁴, Brian Druker⁴, Ross Levine⁵, Ashley Yocum¹⁴, **Uma Borate³**, **Alice Mims³**, John Byrd¹³, Yazan Madanat²*

POSTER PRESENTATIONS III

AML | Abstract #317

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

*Authors: Vijaya Bhatt ¹, Christopher Wichman², Joseph Maakaron³, Richard Stone⁴, Moataz Ellithi¹, Michael Haddadin¹, Lori Maness¹, Soroush Mortaz-Hedjri⁵, Steven Green⁶, Kah Poh (Melissa) Loh⁷, **Sarah Wall⁸**, Krishna Gundabolu*

AML | Abstract #1709

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

*Authors: Naval Daver ¹, Andrew Sochacki², Monzr M. Al Malki³, Eunice Wang⁴, Marianna Muller⁵, Anne Bellon⁵, Sandrine Micallef⁵, David Sallman⁶, **Karilyn Larkin***

AML | Abstract #4228

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

*Authors: Nilesch Kapoor ¹, Deedra Nicolet², Krzysztof Mrózek², Najla Al Ali³, Alex Ambinder⁴, Julia Anderson¹, Lauren Banaszak⁵, Bianca Barredo⁶, Onyee Chan³, Charles Foucar⁷, Andres Gomez-De Leon⁸, Jesus GonzalezLugo⁹, Nicole Lux⁹, Christine McMahon¹⁰, Brittany Ragon¹¹, Kieran Sahasrabudhe⁶, Joshua Zeidner¹², **Alice Mims²**, **Ann-Kathrin Eisfeld²**, Yazan Madanat¹*

AML | Abstract #9462

Clinical study reveals the high efficacy and well-tolerance of venetoclax combined with homoharringtonine, azacitidine, and cytarabine in newly diagnosed AML

Authors: Xin Yan, Yanqing Huang, Chunhua Song, Zheng Ge

AML | Abstract ID#12366

Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement

*Authors: **Jayanshu Jain ¹**, **Ying Huang¹**, Kaitlyn Dvorak-Kornaus¹, Prachi Hirkane², Daniel Corum², **Uma Borate¹***

AML | Abstract ID#12876

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Authors: **Alice Mims 1** , Lai Wei1, Eric McLaughlin1, Jayanshu Jain1, Joshua Zeidner2, Olatoyosi Odenike3, Sangeetha Venugopal4, James Blachly1, Vu Duong5, Anand Patel3, Eric Eisenmann6, Shelley Orwick6, Daelynn Buelow6, Gregory Behbehani1, Richard Little7, Steven Gore8, Sharyn Baker6

AML | Abstract ID#15056

Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/MPN overlap and high-risk CMML

Authors: **Uma Borate 1** , **Shivani Handa1**, **Ying Huang1**, Kaitlyn Dvorak-Kornaus1, **Nicole Grieselhuber1**, **Alice Mims**

AI | Abstract #2011

Deep learning enables automated quantification of hematopoietic stem and progenitor cells (HSPCs) in zebrafish embryos

Authors: Xavier Vesco 1 , Konur Oyman1, Annika Chura1, Wantong Li1, Altan Turkoglu1, Shelby Cabrera1, Zhihong Lin2, 3, Meng Wu3, Blake Peterson2, 3, Sharyn Baker2, 3, Andrew Srisuwananukorn1, **Bradley Blaser1**

CH | Abstract ID#10032

Trends in acute TTP mortality amidst a shifting therapeutic landscape

Authors: Mathew Deucher1, Madhumahita Maddukuri2, **Spero Cataland3**, Senthil Sukumar 2

CLL | ABSTRACT ID#7227

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK18001 and BRUIN CLL-321 studies

Authors: Toby Eyre 1 , Matthew S Davids2, Jeff Sharman3, Paul Barr4, Catherine Coombs5, Wojciech Jurczak6, Koji Izutsu7, Meghan Thompson8, William Wierda9, Ying (denise) Wang10, Marisa Hill10, Donald Tsai10, Ching Ching Leow10, Sarang Abhyankar10, Paolo Ghia11, 12, **Jennifer Woyach13**

GVHD | Abstract ID#1893

BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic GVHD

Authors: Rathan Kumar 1 , Lotus Neidemire-Colley1, Elizabeth Garfinkle2, Camryn Steere1, Simran Surana1, Annie Murray1, Giorgia Giordano1, Olivia Martin1, Emerson Woodbury1, Kara Corps1, Malith Karunasiri1, Mathew Gorr1, Loren Wold1, Kenneth Oestreich1, **Nicole Grieselhuber1**, Bruce Blazar3, Ivan Maillard4, Katherine Miller2, **Hannah Choe1**, **Parvarthi Ranganathan**

GVHD | Abstract ID#8110

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program

Authors: *Leyla Shune* 1 , *Anthony Stein*2, *Damiano Rondelli*3, *Laurie Davis*4, *Shalini Shenoy*5, *Britnie Thomas*6, *Emily Andersen*6, *Elizabeth Jordan*6, *Karim Moftah*6, *Zhenyi Xue*6, **Hannah Choe**7

Lymphoma | Abstract ID#8348

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR Tcell therapies

Authors: *Tae Min Kim* 1 , *Jing-Zhou Hou*2, *Sameh Gaballa*3, *Ranjit Nair*4, *Dai Maruyama*5, *Koji Izutsu*6, *Sumana Devata*7, *Dok Hyun Yoon*8, *Won-Seog Kim*9, **Yazeed Sawalha**10, *Ryan Jacobs*11, *Eliza Hawkes*12, *Ming-Chung Wang*13, *Constantine Tam*14, *Don Stevens*15, *Hisayuki Yokoyama*16, *Jin Seok Kim*17, *Matthew Matasar*18, *Aravind Ramakrishnan*19, *Denise Brennan*20, *David Sermer*21, *Robin Lesley*22, *Xu (Sue) Zhu*20, *Mihail Obrocea*23, *Seok-Goo Cho*

Lymphoma | Abstract ID#9284

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Authors: *Annie Xiao* 1 , *Jarrod Smith*2, *Jomel Meeko Manzano*1, *Lu Chen*1, *Allison Bock*3, *Narendranath Epperla*3, **Yazeed Sawalha**4, *Andrew Jallouk*2, *Shakthi Bhaskar*2, *Lorenzo Falchi*5, *Gilles Salles*5, *Matthew Lunning*6, *Jennifer Crombie*7, *Reid Merryman*7, *Steven Bair*8, *Ajay Major*8, *Amy Ayers*9, *Christine Goth*1, *Geoffrey Shouse*1, *Christopher Flowers*9, *Alexey Danilov*1, *Alex Herrera*1, *Ayushi Chauhan*9, *Sairah Ahmed*9, *Swetha Thiruvengadam*1, *Vivek Patel*2

Lymphoma | Abstract ID#11415

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Authors: *Karan Chohan* 1 , *James Godfrey*2, *Steven Bair*3, *Lorenzo Falchi*4, *Manali Kamdar*3, *Ajay Major*3, *Sonia Godbole*5, *Gilles Salles*4, *Omnia Farahat*1, *Amy Ayers*1, *Ayushi Chauhan*1, *Alex Herrera*2, *Geoffrey Shouse*2, *Sairah Ahmed*1, **Yazeed Sawalha**5

Lymphoma | Abstract ID#11455

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Authors: *Tony Zhuang* 1, 2, *Xiaowen Sun*3, *Lei Feng*3, *Lorenzo Falchi*4, *Ayushi Chauhan*2, *Amy Ayers*2, *Omnia Farahat*2, **Yazeed Sawalha**5, *Geoffrey Shouse*6, *Swetha Thiruvengadam*6, *Steven Bair*7, *Ajay Major*7, *Shakthi Bhaskar*8, *Andrew Jallouk*8, *Allison Bock*9, *Matthew Lunning*10, *Jennifer Crombie*11, *Narendranath Epperla*9, *Alex Herrera*6, *Alexey Danilov*6, *Gilles Salles*4, *Christopher Flowers*2, *Sairah Ahmed*2, *Paolo Strati*1, 12, *Reid Merryman*11, 12

Lymphoma | Abstract ID# 11532

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Authors: *Pierre Stephan 1 , Karan Chohan2, Robert Redd1, Sairah Ahmed2, Christopher Flowers2, Ayushi Chauhan2, Amy Ayers2, Geoffrey Shouse3, Swetha Thiruvengadam3, Alex Herrera3, Allison Bock4, Narendranath Epperla4, Shannon Buckley4, Boyu Hu4, Matthew Lunning5, Gilles Salles6, Lorenzo Falchi6, **Yazeed Sawalha7**, Sonia Godbole7, Andrew Jallouk8, Shakthi Bhaskar8, Ajay Major9, Steven Bair9, Philippe Armand1, Reid Merryman1, Alexey Danilov3, Jennifer Crombie1*

Lymphoma | Abstract ID#12317

Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling

Authors: *Shuyu Shi 1 , **Kathryn Lurain2**, Joseph Schroers-Martin3, Andrea Garofalo3, Jurik Mutter3, Takeshi Sugio3, Soyeong Jun3, Xiaoman Kang3, Feng Tian3, Chih Long Liu3, Mari Olsen3, Wyndham Wilson2, Maximilian Diehn4, Mark Roschewski2, Ash Alizadeh3*

MM | Abstract #8335

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Authors: *Jay Hydren 1 , Rachel Jensen1, Jorge Arturo Hurtado Martinez1, Jennifer Ahlstrom1, Mason Barnes1, Caitlin Costello2, Gurbakhash Kaur3, Meera Mohan4, **Francesca Cottini5**, Douglas Sborov6, Shaji Kumar7, Noopur Raje8, Philippe Moreau9, Maithili Deshpande10, Nodita Gupta-Werner10, Tonya Le Blanc10, Jessica Fowler10, Rahul Banerjee11*